# Damages and Disgorgement in Lilly's Compounded Tirzepatide Cases

Canonical source: https://retacompare.com/research/lilly-damages-disgorgement-123

Eli Lilly · 2026-03-25


    Damages theories in Eli Lilly's compounded tirzepatide cases include lost profits, corrective advertising costs, and disgorgement of defendants' ill-gotten gains. Under the Lanham Act, a prevailing plaintiff may recover defendant's profits, the plaintiff's actual damages, and in exceptional cases, attorneys' fees. Disgorgement is a powerful remedy in this context because many telehealth-affiliated compounders generated substantial revenue from compounded tirzepatide. Early 2026 settlement figures reported in news coverage and public filings suggest that some cases have settled for multi-million-dollar amounts, with additional cases pending.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources